News headlines about Curis (NASDAQ:CRIS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Curis earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 89 out of 100, meaning that recent media coverage is very likely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Curis Inc (CRIS) Under the Watchful Eye of Investors – FLBC News (flbcnews.com)
- Honing in on Shares of Curis, Inc. (NASDAQ:CRIS) – FLBC News (flbcnews.com)
- Technical Levels in Review For Curis Inc (CRIS) – Hayden Business Journal (haydenbusinessjournal.com)
- LBA Has $3 Million Stake in Wells Fargo & Company (newstrendstoday.com)
- EARNINGS SUMMARY: Details of Curis Inc Q2 Earnings Report (rttnews.com)
CRIS has been the topic of a number of recent analyst reports. Cowen and Company reiterated a “buy” rating on shares of Curis in a research note on Friday, May 5th. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, BidaskClub cut Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $5.88.
Shares of Curis (NASDAQ:CRIS) traded down 0.58% during midday trading on Tuesday, reaching $1.70. The company had a trading volume of 341,007 shares. The company has a 50 day moving average of $1.97 and a 200 day moving average of $2.31. Curis has a 12-month low of $1.47 and a 12-month high of $3.72. The firm’s market capitalization is $244.41 million.
Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.01. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. During the same period in the prior year, the company posted ($0.09) EPS. The firm’s revenue was up 23.5% compared to the same quarter last year. Analysts anticipate that Curis will post ($0.40) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was originally published by BBNS and is the property of of BBNS. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://baseballnewssource.com/markets/curis-cris-receives-news-sentiment-score-of-0-12-updated-updated-updated-updated/1196723.html.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with our FREE daily email newsletter.